TargetBeta
PTGER4
prostaglandin E receptor 4 · also EP4 · Prostaglandin receptors
3 programs in company-led studies act on PTGER4, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| BMS-986310rule | Ono Pharmaceutical | phase 3 | 64 running | – | NCIt |
| EP4 Receptor Antagonist YY001rule | Chongqing Claruvis Pharmaceutical | phase 3 | 62 running | – | NCIt |
| EP2/EP4/DP1 Antagonist OKN4395rule | Epkin | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colorectal Neoplasms, 1 program
- Sarcoma, 1 program
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 1, 2027EP4 Receptor Antagonist YY001 · Chongqing Claruvis Pharmaceutical · phase 3 · NCT07478822
- Feb 15, 2028BMS-986310 · Ono Pharmaceutical · phase 3 · NCT06948448
- Jul 2028EP2/EP4/DP1 Antagonist OKN4395 · Epkin · phase 1 · NCT06789172
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.